News Brief: MDMA therapy for PTSD.

News Brief: MDMA therapy for PTSD. : AJN The American Journal of Nursing

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

In the News

AJN, American Journal of Nursing | DOI: 10.1097/01.NAJ.0000997172.65282.23 Metrics

MDMA therapy for PTSD. Those suffering from posttraumatic stress disorder (PTSD) may have a new treatment option—psychedelic therapy. In a confirmatory randomized controlled trial with 104 participants, researchers found that 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy reduced symptoms and functional impairment in people with moderate to severe PTSD. Their findings add to a growing body of evidence that MDMA, commonly known as Ecstasy or Molly, is a safe and effective treatment for PTSD. Participants who received MDMA had significantly better outcomes than those who received placebo, with 71% no longer meeting criteria for a PTSD diagnosis compared with 48% in the placebo group. MDMA was used in psychotherapy until 1985 when the U.S. Drug Enforcement Administration designated it a Schedule 1 drug, making its distribution and use illegal. That may change soon. According to the Multidisciplinary Association for Psychedelic Studies, with the results of this and preceding studies, “MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024.”

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. Article Level Metrics Readers Of this Article Also Read

留言 (0)

沒有登入
gif